Chronic Limb-Threatening IschemiaEspritBTKPASNCT06656364
Esprit BTK Post-Approval Study
A study testing Esprit BTK System in people with Chronic Limb-Threatening Ischemia, run by Abbott Medical Devices at 39 sites in 4 countries.
Trial summary
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Limb-Threatening Ischemia
- What is being tested?
- Esprit BTK System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 39 sitesin 4 countries
- Study dates
- 21 Oct 2024to 30 May 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- General Inclusion Criteria
- Subject must provide written informed consent prior to any study-specific procedures which are not considered standard of care at the site.
- Informed consent can be obtained up to 3 days post-procedure or prior to discharge whichever comes first.
- Subject, or a legally acceptable representative must provide written informed consent per site IRB/EC requirements.
- Subject must be at least 18 years of age.
- Subject has evidence of symptomatic Chronic Limb-Threatening Ischemia (CLTI) with infrapopliteal lesions.
Show all 9Show fewer
- Anatomic Inclusion Criteria
- Subjects who have lesion(s) in an infrapopliteal vessel with reference vessel diameter ≥ 2.5 mm and ≤ 4.0 mm.
- Target lesion(s) must have ≥ 70% stenosis, per visual assessment at the time of the procedure. If needed, quantitative imaging (angiography and intravascular imaging) can be used to aid accurate sizing of the vessels.
Who cannot join
- General Exclusion Criteria
- Subjects who have contraindications to the Esprit BTK System per the instruction for use (IFU).
- Subject is currently participating in another clinical investigation that has not yet completed its primary endpoint.
- Subject or Legally Acceptable Representative (LAR) is unable or unwilling to provide written consent prior to enrollment.
- Subject with life expectancy ≤ 1 year.
- Subject with an unsalvageable limb (as per physician assessment at the time of the index procedure), who is likely to get a below-the-knee amputation.
Show all 9Show fewer
- Anatomic Exclusion Criteria
- Subject has in-stent restenosis in the target vessel or requires a metallic stent as part of a planned treatment or a bailout in the target vessel during the index procedure.
- Subject had been previously treated with Esprit BTK Scaffold(s) within the past 30 days in the same vessel.
Trial locations and contacts
39 sites in 4 countries.
39 sites in 4 countries
United States36 sites
Hendrick Medical Center
Abilene, Texas, 79601
Medical City Arlington
Arlington, Texas, 76014
Grady Clinical Research Center
Atlanta, Georgia, 30303
Ascension St. John Jane Phillips
Bartlesville, Oklahoma, 74006
Carolinas Medical Center
Charlotte, North Carolina, 28203
Erlanger Medical Center
Chattanooga, Tennessee, 37403
Christ Hospital
Cincinnati, Ohio, 45255
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75390
ClinRé 001-100 - Denver
Denver, Colorado, 80220
Charlton Memorial Hospital
Fall River, Massachusetts, 02720
Baylor All Saints Medical Center at Fort Worth
Fort Worth, Texas, 76104
UCSF Fresno
Fresno, California, 93720
HCA Houston Healthcare Medical Center
Houston, Texas, 77004
St. Vincent Hospital
Indianapolis, Indiana, 46260
Jackson Heart Clinic
Jackson, Mississippi, 39216
First Coast Cardiovascular Institute
Jacksonville, Florida, 32256
Johnson City Medical Center Hospital
Johnson City, Tennessee, 37604
Good Samaritan Hospital
Los Angeles, California, 90017
Sorin Medical
New York, New York, 10005
New York University Hospital
New York, New York, 10016
NYU Langone Health
New York, New York, 10016
Mount Sinai Hospital
New York, New York, 10019
New York Presbyterian Hospital-Cornell University
New York, New York, 10021
New York-Presbyterian/Columbia University Medical Center
New York, New York, 10032
Hightower Clinical
Oklahoma City, Oklahoma, 73102
Oklahoma Heart Hospital
Oklahoma City, Oklahoma, 73120
St. Francis Hospital
Roslyn, New York, 11576
Ansaarie Cardiac and Endovascular Center of Excellence
Saint Augustine, Florida, 32080
HonorHealth
Scottsdale, Arizona, 85258
SIU School of Medicine
Springfield, Illinois, 62794
Staten Island University Hospital - North
Staten Island, New York, 10305
Tallahassee Research Institute
Tallahassee, Florida, 32308
Cardiovascular Consultants of South Georgia, LLC
Thomasville, Georgia, 31792
Pima Heart and Vascular Clinical Research
Tucson, Arizona, 85718
North Mississippi Medical Center
Tupelo, Mississippi, 38801
Washington Hospital Center
Washington D.C., District of Columbia, 20010
United Arab Emirates1 site
Al Qassimi Hospital
Sharjah city, Emirate of Sharjah, 3500
About this study
Official title: Esprit BTK Post-Approval Study (Esprit BTK PAS)
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.
- Conditions
- Chronic Limb-Threatening Ischemia
- Being tested
- Esprit BTK System
- Keywords
- ABT-CIP-10519, Esprit BTK System, Infrapopliteal lesions, Post-approval study
- Medical subject headings
- Chronic Limb-Threatening Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Esprit BTK SystemDevice
The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.
| Study group | Role | What they receive |
|---|---|---|
| Esprit BTK System | Experimental | This device, manufactured by Abbott Medical, is intended to be used for improving luminal diameter in infrapopliteal lesions in patients with CLTI. Receives: Device: Esprit BTK System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Effectivenes Endpoint(s): Freedom from clinically-driven target lesion revascularization (CD-TLR)
This effectiveness endpoint was chosen because it allows to assess whether Esprit BTK is effective at maintaining patency (CD-TLR).
Measured: At 1 year
Primary Safety Endpoint(s):MALE at 6 months + POD at 30 days (Major Adverse Limb Event + Peri-Operative Death)
This safety endpoint was chosen because it is a commonly used endpoint to assess the safety of devices used in lower limb treatment, including treatment of lesions below the knee. Additionally, this endpoint assesses whether the device is associated with acute and sub-acute harm such as death and limb loss.
Measured: 6 months + 30 days
Secondary outcomes (6)
All-cause mortality
Death was classified according to the underlying cause. Death within 30 days of the study procedure was classified as procedure-related unless medical history or autopsy findings demonstrated otherwise.
Cardiac death: Any death due to a proximate cardiac cause (e.g., MI, low-output failure, fatal arrhythmia), unwitnessed death, or death of unknown cause. Vascular death: Death caused by noncoronary vascular causes, such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular diseases. Non-cardiovascular death: Any death not covered by the above definitions, such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide, or trauma.
Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Amputation (minor, major)
The definition of amputation applied only to amputations of the limb that was treated. Minor amputation referred to toe amputation(s), ray amputation(s) limited to the metatarsal head and distal half of the metatarsal bone, and trans-metatarsal amputation. Major amputation was defined as limb loss at or proximal to the transtibial level. Major amputations were specified as below-the-knee and above-the-knee amputations.
Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Amputation-free survival
Freedom from above-ankle amputation in the treated limb and death
Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Ankle-Brachial Index (ABI)/Toe-Brachial Index (TBI) progression over time
The ABI was the ratio of the ankle to arm pressure, and it was calculated by dividing the systolic blood pressure in the ankle of one leg by the higher of the two systolic blood pressures in the arms.
An ABI of 0.9-1.4 was considered within the normal range. A reduced ABI (less than 0.9) was consistent with peripheral artery occlusive disease, with values below 0.8 indicating moderate disease and values below 0.5 indicating severe disease. A value greater than 1.4 was considered abnormal, suggesting calcification of the arterial walls and noncompressible vessels, reflecting severe peripheral vascular disease.
Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Rutherford Becker category evolution over time
The Rutherford Becker classification was defined as follows: Grade I (0) Asymptomatic, no hemodynamically significant occlusive disease. (1)Mild claudication. (2) Moderate claudication. (3) Severe claudication. Grade II (4)Ischemic rest pain. Grade III(5) Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia. (6) Major tissue loss extending above the transmetatarsal level, where the functional foot was no longer salvageable.
Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Wound healing, as assessed by investigator
An index wound healing assessment log was required only for subjects who had a wound on the index limb at the time of the index procedure. This was intended to allow the healing of the index wound after treatment to be documented. All subjects that had a wound at the time of the index procedure are required to have an assessment by the site at each follow-up visit even if the index wound was healed at the previous visit. This will confirm that the index wound remains healed. If the index wound at the same location following healing has re-opened, the wound should still be assessed in the same index wound log.
Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Oct 2024
- Study start21 Oct 2024
- Primary completion30 Apr 2027 (estimated)
- Study completion30 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Limb-Threatening IschemiaStudies of the same condition, open and under way.
- More trials run by Abbott Medical DevicesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abbott Medical Devices
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ramon L Varcoe, MBBS, MS, FRACS, PHD, Principal investigator, Prince of Wales Private Hospital, Randwick, NSW, AustraliaSahil Parikh, MD, Principal investigator, New York Presbyterian Hospital, New York, NYBrian G Derubertis, MD, Principal investigator, New York Presbyterian/Cornell, New York, NY
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06656364
- Sponsor's protocol ID
- ABT-CIP-10519
- Acronym
- EspritBTKPAS
- Status last verified
- Mar 2026
- First submitted
- 15 Oct 2024
- Last updated
- 25 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Esprit BTK Post-Approval Study (Esprit BTK PAS)
- ClinicalTrials.gov ID
- NCT06656364
- Acronym / sponsor ID
- EspritBTKPAS / ABT-CIP-10519
- Conditions
- Chronic Limb-Threatening Ischemia
- Keywords
- ABT-CIP-10519, Esprit BTK System, Infrapopliteal lesions, Post-approval study
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Abbott Medical DevicesIndustry (pharma, biotech, devices)
- Study start
- 21 Oct 2024 (actual)
- Primary completion
- 30 Apr 2027 (estimated)
- Study completion
- 30 May 2029 (estimated)
- First posted
- 24 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Esprit BTK System | Experimental | Device: Esprit BTK SystemThis device, manufactured by Abbott Medical, is intended to be used for improving luminal diameter in infrapopliteal lesions in patients with CLTI. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- General Inclusion Criteria
- Anatomic Inclusion Criteria
Key exclusion criteria (9 listed)
- General Exclusion Criteria
- Anatomic Exclusion Criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Esprit BTK SystemThe Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter. | Device | Esprit BTK System |
Primary outcome
Primary Effectivenes Endpoint(s): Freedom from clinically-driven target lesion revascularization (CD-TLR)
Time frame: At 1 year
This effectiveness endpoint was chosen because it allows to assess whether Esprit BTK is effective at maintaining patency (CD-TLR).
Primary Safety Endpoint(s):MALE at 6 months + POD at 30 days (Major Adverse Limb Event + Peri-Operative Death)
Time frame: 6 months + 30 days
This safety endpoint was chosen because it is a commonly used endpoint to assess the safety of devices used in lower limb treatment, including treatment of lesions below the knee. Additionally, this endpoint assesses whether the device is associated with acute and sub-acute harm such as death and limb loss.
6 secondary outcomes
All-cause mortality
Time frame: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Amputation (minor, major)
Time frame: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Amputation-free survival
Time frame: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Ankle-Brachial Index (ABI)/Toe-Brachial Index (TBI) progression over time
Time frame: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Rutherford Becker category evolution over time
Time frame: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Wound healing, as assessed by investigator
Time frame: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Chronic Limb-Threatening Ischemia
Recruiting
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Peripheral Artery Disease, Diabetes Mellitus
RecruitingObservational study
Vessel Recoil in Specific CLTI Populations
Chronic Limb Threatening Ischemia
Not yet recruiting
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scoring in Patients With Femoropopliteal Arterial Disease
Femoropopliteal Disease, Drug Coated Balloon
Active, not recruitingObservational study
Laser Atherectomy and Sirolimus-coated Balloon Angioplasty for CLTI
Chronic Limb Threatening Ischemia
RecruitingEarly Phase 1
Nutrition in Patient With Critical Limb Ischemia
Critical Limb Ischemia, Malnutrition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ramon L Varcoe, MBBS, MS, FRACS, PHD principal investigator
Prince of Wales Private Hospital, Randwick, NSW, Australia
Sahil Parikh, MD principal investigator
New York Presbyterian Hospital, New York, NY
Brian G Derubertis, MD principal investigator
New York Presbyterian/Cornell, New York, NY
39 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Esprit BTK System in people with Chronic Limb-Threatening Ischemia, run by Abbott Medical Devices at 39 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 39 sites in United States, Hong Kong, New Zealand, United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Effectivenes Endpoint(s): Freedom from clinically-driven target lesion revascularization (CD-TLR) (time frame: At 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2026.